(Q41752133)

8 October 2017

title

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice (English)

1 reference

Middle East respiratory syndrome coronavirus

8 October 2017

main subject

0 references

0 references

1 reference

Middle East respiratory syndrome

1 reference

9

1 reference

8 October 2017

8

Albert D M E Osterhaus

1 reference

8 October 2017

Eun Kim

1

1 reference

8 October 2017

Kaori Okada

2

1 reference

8 October 2017

Tom Kenniston

3

1 reference

8 October 2017

V Stalin Raj

4

1 reference

8 October 2017

Mohd M AlHajri

5

1 reference

8 October 2017

Elmoubasher A B A Farag

6

1 reference

8 October 2017

Farhoud AlHajri

7

1 reference

8 October 2017

Andrea Gambotto

10

1 reference

8 October 2017

language of work or name

English

0 references

publication date

3 September 2014

1 reference

8 October 2017

1 reference

8 October 2017

volume

32

1 reference

8 October 2017

issue

45

1 reference

8 October 2017

page(s)

5975-5982

1 reference

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

A decade after SARS: strategies for controlling emerging coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Identification of MERS-CoV in dromedary camels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Virus entry: molecular mechanisms and biomedical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Cellular entry of the SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Effects of a SARS-associated coronavirus vaccine in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Production of adenovirus vectors and their use as a delivery system for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Use of adenoviral vectors as veterinary vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Assessment of route of administration and dose escalation for an adenovirus-based influenza A Virus (H5N1) vaccine in chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Preliminary survey for antibodies against respiratory viruses among slaughter camels (Camelus Dromedarius) in north-eastern nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

New approaches to the prevention and eradication of rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

UpGene: Application of a web-based DNA codon optimization algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Adenovirus-mediated expression of the C-terminal domain of SARS-CoV spike protein is sufficient to induce apoptosis in Vero E6 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Transcriptional profiling of Vero E6 cells over-expressing SARS-CoV S2 subunit: insights on viral regulation of apoptosis and proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Pathology and pathogenesis of severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Rapid generation of a mouse model for Middle East respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.08.058

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

7 January 2021

1 reference

12 December 2020

State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans

1 reference

12 December 2020

Construction of adenovirus vectors through Cre-lox recombination

1 reference

12 December 2020

Immunological responses against SARS-coronavirus infection in humans.

1 reference

12 December 2020

10.1016/J.VACCINE.2014.08.058

Identifiers

DOI

1 reference

8 October 2017

0 references

1 reference